Skip to content

AML-ALL

US Focus Meeting 2026


📍 Estancia La Jolla Hotel, 9700 N Torrey Pines Rd, La Jolla, CA 92037


🗓️ July 9 - 11, 2026


Last Year's Highlights

Dear Colleagues and Friends,

We are delighted to extend our warmest invitation to the US AML-ALL Focus Meeting 2026, to be held at on July 9 - 11, 2026.

Centered around the theme “Updating Knowledge & Clinical Practice in 2026” this meeting provides pivotal collaboration aimed at advancing AML-ALL research and patient treatment.

This meeting presents an opportunity for medical professionals to engage in the exchange of knowledge, expertise, and insights, as well as networking with leading experts. Engage in riveting presentations, participate in thought-provoking debates and roundtable discussions, and connect with peers at informal social gatherings.

 

Co-Chairs of AML-ALL Focus Meeting 2026:

Naval-Daver

Naval Daver, MD
MD Anderson Cancer Center, Houston, TX


Elias-Jabbour

Elias Jabbour, MD
MD Anderson Cancer Center, Houston, TX


Supporters to be announced...
Interested in supporting this meeting? Get in contact:
rebecca.hill@md-education.com

Agenda & Faculty

July 9, 2026 | Day 1  

01:00 PM
Registration Opens

Session I: TBD
Moderated by:

Hagop-Kantarjian-1

Hagop Kantarjian, MD
MD Anderson Cancer Center, Houston, TX


02:00 PM
Updates on CML
Hagop-Kantarjian-1
Hagop Kantarjian, MD
MD Anderson Cancer Center, Houston, TX
02:20 PM
Updates on CLL

WW

William Wierda, MD
MD Anderson Cancer Center, Houston, TX
02:40 PM
Panel Discussion
03:10 PM
Coffee Break

Session II: TBD
Moderated by:

Guillermo-GarciaManero

Guillermo Garcia-Manero, MD
MD Anderson Cancer Center, Houston, TX


03:30 PM
Updates on MDS
Guillermo-GarciaManero
Rami Komrokji, MD
Moffitt Cancer Center, Tampa, FL
03:50 PM
Updates on BPDCN
Naveen-Pemmaraju
Naveen Pemmaraju, MD
MD Anderson Cancer Center, Houston, TX
04:10 PM
Panel discussion & Take-home Points from Day 1
04:40 PM
Adjourn

July 10, 2026 | Day 2  

08:00 AM
Registration Opens

Session III: TBD
Moderated by:

Elias-Jabbour

Elias Jabbour, MD
MD Anderson Cancer Center, Houston, TX


09:00 AM
Molecular Risk Stratification in ALL
Charles Mullighan-1
Charles Mullighan, MD
St. Jude Children’s Research Hospital, Memphis, TN
09:15 AM
How I Treat Ph-Positive ALL
Elias-Jabbour
Elias Jabbour, MD
MD Anderson Cancer Center, Houston, TX
09:30 AM
MRD in Ph-positive ALL BCR:ABL1 vs NGS for IgR

NS

Nicholas Short, MD
MD Anderson Cancer Center, Houston, TX
09:45 AM
Older ALL
Matthew-Wieduwilt-1
Matthew Wieduwilt, MD
Wake Forest University School of Medicine, Winston-Salem, NC
10:00 AM
Panel Discussion
10:30 AM
Coffee Break & Networking

Session IV: TBD
Moderated by:

CD

Courtney DiNardo, MD
MD Anderson Cancer Center, Houston, TX

10:50 AM
Genetic and Molecular Diagnostics in AML
Sanam-Loghavi-1
Sanam Loghavi, MD
MD Anderson Cancer Center, Houston, TX
11:05 AM
Frontline Fit NPM1 Mutated AML: What Are the Current Data and Where Do We See This Evolving in the Near Future

AZ

Amer Zeidan, MD
Yale School of Medicine, New Haven, CT
11:20 AM
Menin Inhibitors in R/R AML: Updates on Single Agent Efficacy, Safety, Resistance and Role of Second Generation Menin Inhibitors

AF

Amir Fathi, MD
Massachusetts General Hospital, Boston, MA
11:35 AM
Moving Beyond Single-Agent Menin Inhibitors: Emerging Data and Optimization of Menin Inhibitor Combos

JZ

Joshua Zeidner, MD
UNC School of Medicine, Chapel Hill, NC
11:50 PM
Panel Discussion
12:20 PM
Industry Supported Independent Expert Discussion
01:05 PM

Lunch Break

Session V: TBD
Moderated by:

AL

Aaron Logan, MD
UCSF Health, San Francisco, CA

 

01:55 PM
Management of ALL: Closing the Gap Between Centers of Excellence and Underserved Communities

LM

Lori Muffly, MD
Stanford Medicine, CA
02:10 PM
MRD Eradication and When Allogeneic Transplant is Still Needed

AL

Aaron Logan, MD
UCSF Health, San Francisco, CA
02:25 PM
How Much Chemotherapy is Still Needed in Newly Diagnosed Adults With ALL
Hagop-Kantarjian-1
Hagop Kantarjian, MD
MD Anderson Cancer Center, Houston, TX
02:40 PM
Questions Re Pediatric Regimens: Less Toxic, Equally Effective?

WS

Wendy Stock, MD
The University of Chicago Medicine, Chicago, IL
02:55 PM
Panel Discussion
03:25 PM
Coffee Break & Networking

Session VI: TBD
Moderated by:

Naval-Daver

Naval Daver, MD
MD Anderson Cancer Center, Houston, TX

 

03:45 PM
AZA+VEN for all – or Not Really?
Amir-Fathi-1
Amir Fathi, MD
Massachusetts General Hospital, Boston, MA
04:00 PM
Triplets in AML: Are We There Yet and If So for Which Ones Are We Really There?
Naval-Daver
Naval Daver, MD
MD Anderson Cancer Center, Houston, TX
04:15 PM
How do I use IDH Inhibitors in Frontline and R/R AML AML
Courtney-Dinardo
Courtney DiNardo, MD
MD Anderson Cancer Center, Houston, TX
04:30 PM
Optimizing Measurement of MRD in AML and How Should We Use MRD in Guiding the Treatment of AML
Christopher-Hourigan
Christopher Hourigan, MD
Virginia Tech FBRI Cancer Research Center, Blacksburg, VA
04:45 PM
Panel Discussion
05:15 PM
Special Lecture: AML 2026 Future Directions

HK

Hagop Kantarjian, MD
MD Anderson Cancer Center, Houston, TX
05:30 PM
Question & Adjourn

July 11, 2026 | Day 3  

08:00 AM
Registration Opens

Session VII: TBD
Moderated by:

BS

Bijal Shah, MD
Moffitt Cancer Center, Tampa, FL

 

09:00 AM
Novel Agents in R/R ALL: SQ Blina
Elias-Jabbour
Elias Jabbour, MD
MD Anderson Cancer Center, Houston, TX
09:15 AM
Other Bispecifics and ADC

IA

Ibrahim Aldoss, MD
City of Hope Comprehensive Cancer Center, Duarte, CA
09:30 AM
How to Optimize Outcomes Post CAR T

BS

Bijal Shah, MD
Moffitt Cancer Center, Tampa, FL
09:45 AM
Optimizing Maintenance Approaches in Non-Transplanted Patients With AML
Jae-Park
Jae Park, MD
Memorial Sloan Kettering Cancer Center, New York City, NY
10:00 AM
Optimizing Post-Transplant Maintenance Approaches and the ACT Platform Successes in SCT

NJ

Nitin Jain, MD
MD Anderson Cancer Center, Houston, TX
10:15 AM
Panel Discussion
10:45 AM
Coffee Break & Networking

Session VIII: TBD
Moderated by:

TBD
KOL TBD

 

11:05 AM
Genomic Strategies to Guide the Choice of Intensive Treatment Strategies in NonFLT3m AML
Eunice-Wang
Eunice Wang, MD
Roswell Park Comprehensive Cancer Center, Buffalo, NY
11:20 AM
Frontline Treatment of FLT3-ITD Mutated AML – Where are we Headed
Alexander-Perl
Alexander Perl, MD
University of Pennsylvania, Philadelphia, PA
11:35 AM
Optimizing Maintenance Approaches in Non-Transplanted Patients With AML
Tapan-Kadia
Tapan Kadia, MD
MD Anderson Cancer Center, Houston, TX
11:50 AM
Optimizing Post-Transplant Maintenance Approaches and the ACT Platform Successes in SCT
Charlie-Craddock
Charlie Craddock, MD
Queen Elizabeth Hospital Birmingham, UK
12:05 PM
Panel Discussion
12:35 PM
Industry Supported Independent Expert Discussion
01:20 PM
Lunch & Networking

Session IX: TBD
Moderated by:

LM

Lori Muffly, MD
Stanford Medicine, CA

 

02:10 PM
TP53 Mutated ALL and ALL With Myeloid Mutations

KT

Koichi Takahashi, MD
MD Anderson Cancer Center, Houston, TX
02:25 PM
BH3 Mimetics in ALL
Daniel-Deangelo
Daniel J. DeAngelo, MD
Dana-Farber Cancer Institute, Boston, MA
02:40 PM
CAR T-cells of T-ALL
Armin-Ghobadi-1
Armin Ghobadi, MD
Washington University School of Medicine, St. Louis, MO
02:55 PM
MPAL Management

JS

Jayastu Senapati, MD
MD Anderson Cancer Center, Houston, TX
03:10 PM
Panel Discussion
03:40 PM
Coffee Break & Networking

Session X: TBD
Moderated by:

CD

Courtney DiNardo, MD
MD Anderson Cancer Center, Houston, TX

 

04:00 PM
Developing CARTs in AML: Current Status, Challenges, Emerging Constructs and Future Directions

JP

Jae Park, MD
Memorial Sloan Kettering Cancer Center,
New York, NY
04:15 PM
CD33 and CD123 ADCs in AML: From GO to CD123 – Has the Path Been Paved?
Farhad-Ravandi
Farhad Ravandi, MD
MD Anderson Cancer Center, Houston, TX
04:30 PM
Optimal Dose of VEN in Frontline HMAVEN and Implications for Future Triplets/Combos
Uma-Borate
Uma Borate, MD
The Ohio State University, Ohio
04:45 PM
Panel Discussion & Take-home Points
05:15 PM
Adjourn

Rebecca Hill
Project Manager

How long has Rebecca Hill been in the business?

Rebecca Hill has been with MD Education since 2022

About Rebecca Hill

I am a dedicated Senior Project Manager at MD Education, specialising in coordinating global medical conferences. I have a passion for organisation and detail, and I pride myself on ensuring seamless execution of educational events. My expertise lies in orchestrating logistics and fostering collaboration among diverse teams.

Rebecca-Hill